No Data
Express News | Teva : HSBC Raises Target Price to $23 From $20
Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
loading...